Treating iga nephropathy: Quid novi?

Discovery Medicine

Volumn 17, Issue 93, 2014, Pages 131-138

  Hartono, Choli ^a,b   Muthukumar, Thangamani ^b  

^a ROGOSIN INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BORTEZOMIB; CORTICOTROPIN; CYCLOPHOSPHAMIDE; FISH OIL; GLUCOCORTICOID; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN KAPPA CHAIN; IRBESARTAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYUNSATURATED FATTY ACID; PROTEIN KINASE D; RAMIPRIL; RITUXIMAB; UBIQUITIN CONJUGATING ENZYME E2;

ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; GENE EXPRESSION; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TONSILLECTOMY;

ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOANTIGENS; FISH OILS; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84896931649     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. rd, Klippel JH, Balow JE, Le Riche NGH, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314:614-619, 1986
2. Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol 13:142-148, 2002
3. Berger J, Hinglais N. Les dépôts intercapillaires d'IgA-IgG. J Urol Nephrol 74:694-695, 1968
4. Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PHM, Tamouza H, Jamin A, Bex-Coudrat J, Gestin A, Boumediene A, Arcos-Fajardo M, England P, Pillebout E, Walker F, Daugas E, Vrtosvnik F, Flamant M, Benhamou M, Cogne M, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 209(4):793-806, 2012
5. Berthoux F, El Deeb S, Mariat C, Diconne E, Laurent B, Thibaudin L. Antithymocyte globulin (ATG) induction therapy and disease recurrence in renal transplant recipients with primary IgA nephropathy. Transplantation 85:1505-1507, 2008
6. Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol 22:752-761, 2011
7. Bomback AS, Tumlin JA, Baranski J, Bourdeau JE, Besarab A, Appel AS, Radhakrishnan J, Appel GB. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther 5:147-153, 2011
8. Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am J Nephrol 36:58-67, 2012
9. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347(10):103-109, 2002
10. Clayton P, McDonald S, Chadban S. Steroids and recurrent IgA nephropathy after kidney transplantation. Am J Transplant 11:1645-1649, 2011
11. Czerkinsky C, Koopman WJ, Jackson S, Collins JE, Crago SS, Schrohenloher RE, Julian BA, Galla JH, Mestecky J. J Clin Invest 77(6):1931-1938, 1986
12. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 36(2):227-237, 2000
13. Donadio JV Jr. Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin Proc 66:1018-1028, 1991
14. Donadio JV Jr., Bergstralh EJ, Offord KP, Spencer DC, Holley KE. The Mayo Nephrology Collaborative Group. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331:1194-1199, 1994
15. Donadio JV, Grande JP. IgA nephropathy. N Engl J Med 347(10):738-748, 2002
16. Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial. Nephrol Dial Transplant 24:156-160, 2009
17. rd. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med 3(85):85ra46, 2011
18. Forslund T, Sikio A, Anttinen J. IgA nephropathy in a patient with IgG lamda light-chain plasmacytoma: a rare coincidence. Nephrol Dial Transplant 22(9):2705-2708, 2007
19. Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G. Nephrol Dial Transplant 20:2139-2145, 2005
20. Gong R. The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol 8(2):122-128, 2011
21. Grupe WE, Heymann W. Cytotoxic drugs in steroid-resistant renal disease. Alkylating and antimetabolic agents in the treatment of nephrotic syndrome, lupus nephritis, chronic glomerulonephritis, and purpura nephritis in children. Am J Dis Child 112(5):448-458, 1966
22. Hartono C, Chung M, Kuo SF, Seshan SV, Muthukumar T. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J Nephrol 27(1):103-106, 2014
23. Hartono C, Muthukumar T, Suthanthiran M. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med 3(9):a015487, 2013
24. Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, Webster AC. Treatment for lupus nephrtis. Cochrane Database Sys Rev 12:CD002922, 2012
25. Kidney Disease Improving Global Outcomes: KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int 2:139-172, 2012
26. Kobayashi Y, Fujii K, Hiki Y, Tateno S. Steroid therapy in IgA nephropathy: a prospective pilot study in moderate proteinuric cases. Q J Med 61(234):935-943, 1986
27. Lai KN, Leung JCK, Chan LYY, Saleem MA, Mathieson PW, Lai FM, Tang SCW. Activation of podocytes by mesangial-derived TNF-a: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol 294:F945-F955, 2008
28. Lai KN, Leung JCK, Chan LYY, Saleem MA, Mathieson PW, Tam KY, Xiao J, Lai FM, Tang SCW. Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy. Nephrol Dial Transplant 24:62-72, 2009
29. Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YFC. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 65:1842-1849, 2004
30. Mestecky J, Raska M, Julian BA, Gharavi AG, Renfrow MB, Moldoveanu Z, Novak L, Matousovic K, Novak J. IgA Nephropathy: Molecular mechanisms of the disease. Annu Rev Pathol Mech Dis 8:217-240, 2013
31. Mestecky J, Tomana M, Crowley-Nowick PA, Moldoveanu Z, Julian BA, Jackson S. Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenetic factor in IgA nephropathy. Contrib Nephrol 104:172-182, 1993
32. Mulay AV, van Walraven C, Knoll GA. Impact of immunosuppressive medication on the risk of renal allograft failure due to recurrent glomerulonephritis. Am J Transplant 9:804-811, 2009
33. Mustonen J, Pasternack A, Rantala I. The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy. Clin Nephrol 20:172-176, 1983
34. Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int 69:1455-1458, 2006
35. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 9(1):201-209, 2009
36. Ponticell C, Passerini P, Salvadori M, Manno C, Viola BF, Pasquali S, Mandolfo S, Messa P. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 47:233-240, 2005
37. Pozzi C, Andrulli S, Pani A, Scaini P, Del Vecchio L, Fogazzi G, Vogt B, De Cristofaro V, Allergi L, Cirami L, Procaccini AD, Locatelli F. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol 21:1783-1790, 2010
38. Reich HN, Troyanov S, Scholey JW, Cattran DC. for the Toronto Glomerulonephritis Registry. J Am Soc Nephrol 18:3177-3183, 2007
39. Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GFM. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Sys Rev 16(3):CD003962, 2011
40. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med 353:1711-1723, 2005
41. Samuels JA, Strippoli GFM, Craig JC, Schena FP, Molony DA. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Sys Rev (4):CD003965, 2003
42. Shortt J, Oh DH, Opat SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 368:90-92, 2013
43. Sigdel TK, Woo SH, Dai H, Khatri P, Li L, Myers B, Sarwal MM, Lafayette RA. Profiling of autoantibodies in IgA nephropathy, an integrative antibiomics approach. Clin J Am Soc Nephrol 6:2775-2784, 2011
44. Silva FG, Chander P, Pirani CL, Hardy MA. Disappearance of glomerular mesangial IgA deposits after renal allograft transplantation. Transplantation 33:241-246, 1982
45. Stangou M, Ekonomidou D, Giamalis P, Liakou H, Tsiantoulas A, Pantzaki A, Papagianni A, Efstratiadis G, Alexopoulos E, Memmos D. Steroids and azathioprine in the treatment of IgA nephropathy. Clin Exp Nephrol 15(3):373-380, 2011
46. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, Shiohira T, Shimizu A, Tsuruta Y, Amemiya N, Ogawa T, Uchida K, Tsuchiya K, Nitta K. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 117:c98-c105, 2011
47. Suzuki H, Fan R, Zhang Z, Brown R, Hall S, Julian BA, Chatham WW, Suzuki Y, Wyatt RJ, Moldoveanu Z, Lee JY, Robinson J, Tomana M, Tomino Y, Mestecky J, Novak J. J Clin Invest 119(6):1668-1677, 2009
48. Tan CH, Loh PT, Yang WS, Chan CM. Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review. Singapore Med J 49(10):780-785, 2008
49. Tang SCW, Tang AWC, Wong SSH, Leung JCK, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int 77:543-549, 2010
50. Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int 52:509-516, 1997
51. Walker RG, Yu SH, Owen JE, Kincaid-Smith P. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial. Clin Nephrol 34(3):103-107, 1990
52. Woo KT, Chiang GS, Lim CH. Follow-up renal biopsies in IgA nephritic patients on triple therapy. Clin Nephrol 28:304-305, 1987
53. Wyatt RJ, Julian BA. IgA Nephropathy. N Engl J Med 368:2402-2414, 2013
54. Xu G, Tu W, Jiang D, Xu C. Mycophenolate mofetil treatment for IgA nephropathy: a meta-analysis. Am J Nephrol 29(5):362-367, 2009